<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574428</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-006</org_study_id>
    <nct_id>NCT03574428</nct_id>
  </id_info>
  <brief_title>Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeNeuro Australia PTY Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeNeuro SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, double-blind, placebo controlled, parallel group, dose-escalating,&#xD;
      randomised study designed to assess and compare the safety and tolerability, PK, and&#xD;
      immunogenicity of GNbAC1 administered as a single dose at 4 different dose levels of 36, 60,&#xD;
      85 and 110 mg/kg.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Actual">November 2, 2018</completion_date>
  <primary_completion_date type="Actual">November 2, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single ascending doses of GNbAC1 (Serious Adverse Events, Adverse Events)</measure>
    <time_frame>57 days</time_frame>
    <description>Serious Adverse Events (SAE), Adverse Events (AE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK): GNbAC1 serum concentrations over time</measure>
    <time_frame>57 days</time_frame>
    <description>GNbAC1 serum concentrations over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Antibodies against GNbAC1 (ADA)</measure>
    <time_frame>57 days</time_frame>
    <description>Antibodies against GNbAC1 (ADA)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNbAC1</intervention_name>
    <description>Monoclonal Antibody infused i.v.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GNbAC1 Placebo</intervention_name>
    <description>Equivalent to GNbAC1 Buffer</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers&#xD;
&#xD;
          -  Negative urine drug screen&#xD;
&#xD;
          -  Have signed the informed consent.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  History of serious adverse reactions or hypersensitivity to any drug.&#xD;
&#xD;
          -  Use of any prescription medication within 30 days prior to the administration of&#xD;
             investigational product and/or non-prescription medication (including herbal and&#xD;
             natural remedies, homeopathy, vitamins, and minerals) within 7 days prior to the&#xD;
             administration of investigational product or anticipated use of any concomitant&#xD;
             medication during the study. Permissible exceptions are paracetamol up to 4g/day&#xD;
             ceasing a minimum of 12 hours prior to infusion and Ibuprofen up to 1.2g/day ceasing a&#xD;
             minimum of 24 hours prior to infusion. Paracetamol and ibuprofen are allowed during&#xD;
             the study, but only 24 hours after completion of the administration of investigational&#xD;
             product.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scientia Clinical Research Ltd</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temelimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

